Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, have entered into an exclusive license agreement for the development and commercialization of leriglitazone, Minoryx’s brain penetrating disease-modifying PPAR-γ agonist.   Under the terms of the agreement, Sperogenix will receiv...